Lab testing of biospecimens collected from participants of the NCI's HPV vaccine studies
Ended Awarded Last action
- Contract number
- 75N91022F00002
- Awardee
-
Fundacion Inciensa UEI KDL2VERNRKA5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,385,092
Award facts
- Opportunity
-
- HPV202301 Solicitation number
- Contract value 47% obligated
-
- $1,385,092.00 Current, with exercised options
- $2,931,937.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541720 Research and Development in the Social Sciences and Humanities
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Sealed Bid
- Pricing
- Firm Fixed Price
- Place of performance
- Costa Rica
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Exercise an Option | $649,871 | |
| Exercise an Option | $537,967 | |
| Original award | $197,254 |
About this award
The National Cancer Institute awarded a firm fixed-price delivery order valued at approximately $2.93 million to Fundacion Inciensa, a Costa Rica-based non-profit research organization, for laboratory testing of biospecimens collected from participants in the NCI's human papillomavirus (HPV) vaccine studies. The contract, awarded on September 26, 2022, with a completion date of September 25, 2027, supports evaluation of single-dose protection afforded by prophylactic HPV vaccines. The work will be performed in Costa Rica, and no set-aside designation was used for this award. This delivery order was issued under the organization's larger Indefinite Delivery Contract with the NCI, valued at $49 million through August 2034, which establishes an ongoing research partnership for epidemiological, clinical, and laboratory services related to vaccine trials and infectious disease prevention.
Fundacion Inciensa has demonstrated substantial expertise in supporting the NCI's research objectives, with a federal contract portfolio totaling approximately $36 million across multiple awards focused on HPV vaccine efficacy studies, clinical trials, and biospecimen analysis. The organization, registered in SAM.gov since 2004, specializes in providing epidemiological and laboratory research services with a particular focus on infectious disease and vaccine research. A modification issued in March 2025 de-scoped Option 3 of the contract as part of the Department of Government Efficiency cost efficiency initiative, reflecting the government's ongoing efforts to optimize federal spending while maintaining the core research objectives.
Quick answers
Who was awarded contract 75N91022F00002?
75N91022F00002 was awarded to Fundacion Inciensa by National Cancer Institute (National Institutes of Health) on September 26, 2022.
How much is contract 75N91022F00002 worth?
The government has obligated $1,385,092 on 75N91022F00002. Its potential value, with all options, is $2,931,937.
Is contract 75N91022F00002 an order under another contract?
Yes. 75N91022F00002 is a delivery order under HHSN261201700012I, an indefinite delivery contract.
Was contract 75N91022F00002 competed?
The extent of competition for 75N91022F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award